This is a summary of the European Public Assessment Report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part of the EPAR).
Therapeutic Indication
### Therapeutic indication First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients. Fareston is not recommended for patients with estrogen receptor negative tumours.
Therapeutic Area (MeSH)
N/AATC Code
L02BA02
ATC Item
toremifene
Pharmacotherapeutic Group
Endocrine therapy
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| toremifene | N/A | 托瑞米芬 |
EMA Name
Fareston
Medicine Name
Fareston
Aliases
N/ANo risk management plan link.
